Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To further assess the potential role of Janus kinase inhibition in the development of malignancies, we performed an integrated analysis of data from the tofacitinib RA clinical development progr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Rheum Dis
Main Authors: Curtis, Jeffrey R, Lee, Eun Bong, Kaplan, Irina V, Kwok, Kenneth, Geier, Jamie, Benda, Birgitta, Soma, Koshika, Wang, Lisy, Riese, Richard
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2016
Assuntos:
Clinical and Epidemiological Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4853586/
https://ncbi.nlm.nih.gov/pubmed/25902789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2014-205847
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares